articles
- Expanding the toolbox for reversal of anticoagulation in chronic kidney disease. 74:1769-1771. 2019
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. 71:1021-1034. 2018
- Myocardial infarction produces sustained proinflammatory endothelial activation in remote arteries. 72:1015-1026. 2018
- Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. 72:2040-2050. 2018
- Using digital health technology to better generate evidence and deliver evidence-based care. 71:2680-2690. 2018
- Interventions for increasing physical activity from "Ingenious Toys" to mHealth. 67:2464-2466. 2016
- Moving from digitalization to digitization in cardiovascular care why is it important, and what could it mean for patients and providers?. 66:1489-1496. 2015
- Genetic implication of a novel thiamine transporter in human hypertension. 63:1542-1555. 2014
- Human heart rate: heritability of resting and stress values in twin pairs, and influence of genetic variation in the adrenergic pathway at a microribonucleic acid microRNA motif in the 3'-UTR of cytochrome b561. 63:358-368. 2014
- RESPONSE: Time for the pager to enter retirement. 64:2705-2705. 2014
- Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention the gift (genotype information and functional testing) study. 59:1928-1937. 2012
- Neuropeptide y (npy) genetic variation in the human promoter alters glucocorticoid signaling, yielding increased npy secretion and stress responses. 60:1678-1689. 2012
- Association of mortality with years of education in patients with st-segment elevation myocardial infarction treated with fibrinolysis. 57:138-146. 2011
- Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension. 55:1463-1475. 2010
- Neuropeptide y(1) receptor npy1r discovery of naturally occurring human genetic variants governing gene expression in cella as well as pleiotropic effects on autonomic activity and blood pressure in vivo. 54:944-954. 2009
- The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. 54:1935-1945. 2009
- Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. 52:1693-1701. 2008
- Naturally occurring human genetic variation in the 3 '-untranslated region of the secretory protein chromogranin a is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. 52:1468-1481. 2008
- Platelet function monitoring in patients with coronary artery disease. 50:1822-1834. 2007
- Future use of genomics in coronary artery disease. 50:1933-1940. 2007
- In unstable angina or non-st-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?. 49:849-854. 2007
- Lack of evidence of a clopidogrel-statin interaction in the charisma trial. 50:291-295. 2007
- Long-term outcome and its predictors among patients with st-segment elevation myocardial infarction complicated by shock: Insights from the gusto-i trial. 50:1752-1758. 2007
- Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial. 49:1982-1988. 2007
- Redefining risk in acute coronary syndromes using molecular medicine. 49:279-289. 2007
- Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. 47:155-162. 2006
- Optimal timing for pre-treatment with before percutaneous the initiation of 300 mg clopidogrel coronary intervention. 47:939-943. 2006
- The influence of peripheral arterial disease on outcomes - a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. 48:1567-1572. 2006
- Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - results from the clopidogrel for the reduction of events during observation (credo) trial. 46:761-769. 2005
- The genomic basis of myocardial infarction. 46:1456-1465. 2005
- Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus - an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (replace)-2 trial. 45:1932-1938. 2005
- Variability in platelet responsiveness to clopidogrel among 544 individuals. 45:246-251. 2005
- Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. 44:2133-2136. 2004
- Aspirin dose and six-month outcome after an acute coronary syndrome. 43:972-978. 2004
- Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. 43:1908-1914. 2004
- Economic evaluation of bivalirudin with provisional glycoprotein iib/iiia inhibition versus heparin with routine glycoprotein iib/iiia inhibition for percutaneous coronary intervention - results from the replace-2 trial. 44:1792-1800. 2004
- Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein iib/iiia blockade compared to heparin with routine glycoprotein iib/iiia blockade - a replace-2 substudy. 44:1194-1199. 2004
- Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. 43:936-942. 2004
- Outcome of acute st-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein iib/iiia inhibition - lessons from the gusto v trial. 43:542-548. 2004
- A guide to therapeutic decision-making in patients with non-st-segment elevation acute coronary syndromes. 41:123S-129S. 2003
- A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. 41:961-965. 2003
- Angiographic variables predict increased risk for adverse ischernic events after coronary stenting with glycoprotein iib/iiia inhibition - results from the target trial. 42:981-988. 2003
- Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival - results from the do tirofiban and reopro give similar efficacy outcome trial (target). 42:1188-1195. 2003
- Troponin and c-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome - a gusto-iv substudy. 41:916-924. 2003
- Troponin t and quantitative st-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. 41:371-380. 2003
- Association between ck-mb elevation after percutaneous or surgical revascularization and three-year mortality. 40:1961-1967. 2002
- Early angioplasty in acute coronary syndromes without persistent st-segment elevation improves outcome but increases the need for six-month repeat revascularization - an analysis of the pursuit trial. 39:1924-1929. 2002
- Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction - the integrilin and low-dose thrombolysis in acute myocardial infarction (intro ami) trial. 39:377-386. 2002
- Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. 39:9-14. 2002
- Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. 40:669-675. 2002
- Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. 40:1034-1040. 2002
- Prognostic significance of elevated troponin i after percutaneous coronary intervention. 39:1738-1744. 2002
- The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. 39:22-29. 2002
- Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. 37:2059-2065. 2001
- Prevention of intimal hyperplasia with recombinant soluble p-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. 38:577-582. 2001
- Prognostic value of st segment depression in acute coronary syndromes: Insights from paragon-a applied to gusto-iib. 38:64-71. 2001
- Reactivation of ischemic events in acute coronary syndromes: Results from gusto-iib. 37:1001-1007. 2001
- Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. 37:492-498. 2001
- Abciximab reduces mortality in diabetics following percutaneous coronary intervention. 35:922-928. 2000
- Application of a continuous regression model of restenosis to saphenous vein grafts after successful percutaneous transluminal coronary angioplasty or directional coronary atherectomy. 35:619-623. 2000
- Clinical benefit of glycoprotein iib/iiia blockade with abciximab is independent of gender - pooled analysis from epic, epilog and epistent trials. 36:381-386. 2000
- Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: Lessons from the gusto-iib angioplasty substudy. 35:1502-1512. 2000
- Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. 35:563-568. 2000
- Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction - results from the speed (gusto-4 pilot) trial. 36:1489-1496. 2000
- Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. 36:75-83. 2000
- Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. 35:1103-1115. 2000
- Platelet glycoprotein iib/iiia blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent st-segment elevation. 36:685-692. 2000
- Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. 35:136-143. 2000
- Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. 33:88-96. 1999
- Comparing physician-specific two-year patient outcomes after coronary angiography - methodologic issues and results. 33:1278-1285. 1999
- Effect of age on outcome with primary angioplasty versus thrombolysis. 33:412-419. 1999
- Outcome of hispanic patients treated with thrombolytic therapy for acute myocardial infarction - results from the gusto-i and -iii trials. 34:1729-1737. 1999
- The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. 33:1269-1277. 1999
- The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization - insights from the epic trial. 33:647-653. 1999
- Acute myocardial infarction and complete bundle branch block at hospital admission: Clinical characteristics and outcome in the thrombolytic. 31:105-110. 1998
- Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: The gusto-i experience. 32:634-640. 1998
- Cost of cardiac care in the three years after coronary catheterization in a contained care system: Critical determinants and implications. 31:1306-1313. 1998
- Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. 31:31-36. 1998
- Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. 31:1466-1473. 1998
- Heparin-induced thrombocytopenia. 31:1449-1459. 1998
- Influence of a randomized clinical trial on practice by participating investigators: Lessons from the coronary angioplasty versus excisional atherectomy trial (caveat). 31:265-272. 1998
- Modifiable risk factors for vascular access site complications in the impact ii trial of angioplasty with versus without eptifibatide. 31:1518-1524. 1998
- Myonecrosis after revascularization procedures. 31:241-251. 1998
- Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. 32:311-319. 1998
- Potential impact of evidence-based medicine in acute coronary syndromes: Insights from gusto-iib. 32:2023-2030. 1998
- Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. 32:936-941. 1998
- Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the gusto-iib trial. 31:1493-1498. 1998
- Recurrent ischemia after thrombolysis: Importance of associated clinical findings. 31:94-102. 1998
- Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. 32:1619-1623. 1998
- The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-q-wave myocardial infarctions. 32:1366-1370. 1998
- Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the gusto-i trial. 31:497-505. 1998
- 28th Bethesda Conference. Task force 5: Assessment, approval, and regulation of new technology. 29:1171-1179. 1997
- Atrial fibrillation in the setting of acute myocardial infarction: The gusto-i experience. 30:406-413. 1997
- Coronary revascularization surgery after myocardial infarction: Impact of bypass surgery on survival after thrombolysis. 29:240-249. 1997
- Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the gusto-i trial. 30:1606-1610. 1997
- Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein iib/iiia receptor blockade by abciximab (c7e3 fab) among patients with unstable angina undergoing percutaneous coronary revascularization. 30:149-156. 1997
- Gender and acute myocardial infarction: Is there a different response to thrombolysis?. 29:35-42. 1997
- Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. 30:171-179. 1997
- Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. 29:808-816. 1997
- Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: Observations from the gusto-i study. 30:708-715. 1997
- Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The gusto-i experience. 28:1661-1669. 1996
- Coronary artery stents. 28:782-794. 1996
- Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty. 28:106-111. 1996
- Early discharge in the thrombolytic era: An analysis of criteria for uncomplicated infarction from the global utilization of streptokinase and t-pa for occluded coronary arteries (gusto) trial. 27:625-632. 1996
- Effect of subintimal resection on initial outcome and restenosis for native coronary lesions and saphenous vein graft disease treated by directional coronary atherectomy - a report from the caveat i and ii investigators. 28:645-651. 1996
- Increased risk of non-q wave myocardial infarction after directional atherectomy is platelet dependent: Evidence from the epic trial. 28:849-855. 1996
- Late assessment of thrombolytic efficacy (late) study: Prognosis in patients with non-q wave myocardial infarction. 27:1327-1332. 1996
- Prognostic significance of precordial st segment depression during inferior myocardial infarction in the thrombolytic era: Results in 16,521 patients. 28:305-312. 1996
- Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. 28:1111-1118. 1996
- Role of platelets in restenosis after percutaneous coronary revascularization. 28:1643-1651. 1996
- Selective inhibition of factor xa is more efficient than factor viia-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. 28:1858-1865. 1996
- Time from symptom onset to treatment and outcomes after thrombolytic therapy. 27:1646-1655. 1996
- Abrupt closure - the caveat-i experience. 26:1494-1500. 1995
- Cardiac rupture associated with thrombolytic therapy - impact of time to treatment in the late assessment of thrombolytic efficacy (late) study. 25:1063-1068. 1995
- Characteristics and consequences of myocardial-infarction after percutaneous coronary intervention - insights from the coronary angioplasty versus excisional atherectomy trial (caveat). 25:1693-1699. 1995
- Contemporary reperfusion therapy for cardiogenic-shock - the gusto-i trial experience. 26:668-674. 1995
- Directional atherectomy versus balloon angioplasty for coronary ostial and nonostial left anterior descending coronary-artery lesions - results from a randomized multicenter trial. 25:1380-1386. 1995
- Evaluation of paradoxic beneficial-effects of smoking in patients receiving thrombolytic therapy for acute myocardial-infarction - mechanism of the smokers paradox from the gusto-i trial, with angiographic insights. 26:1222-1229. 1995
- Lessons we have learned from the gusto trial. 25:S10-S17. 1995
- Percutaneous revascularization of ostial saphenous-vein graft stenoses. 26:955-960. 1995
- Peripheral vascular complications in the coronary angioplasty versus excisional atherectomy trial (caveat-i). 26:922-930. 1995
- Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991 - improved in-hospital and 12-month results. 25:1137-1142. 1995
- Treating menstruating women with thrombolytic therapy - insights from the global utilization of streptokinase and tissue-plasminogen activator for occluded coronary-arteries (gusto-i) trial. 26:1651-1656. 1995
- Cardiac angiography without cine film - erecting a tower-of-babel in the cardiac-catheterization laboratory. 24:834-837. 1994
- Cell-adhesion molecules in coronary-artery disease. 24:1591-1601. 1994
- Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial-infarction. 23:891-898. 1994
- Early angiography cannot predict postthrombolytic coronary reocclusion - observations from the gusto angiographic study. 24:1439-1444. 1994
- Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation. 24:1207-1212. 1994
- Pulmonary hemorrhage after intracoronary stent placement. 24:91-94. 1994
- Randomized trials of directional coronary atherectomy - implications for clinical-practice and future investigation. 24:431-439. 1994
- Balloon angioplasty for the treatment of lesions in saphenous-vein bypass grafts. 21:1539-1549. 1993
- Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty - a matched case-control study. 21:866-875. 1993
- Is traditionally defined complete revascularization needed for patients with multivessel disease treated by elective coronary angioplasty. 22:1289-1297. 1993
- Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. 21:597-603. 1993
- Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty - clinical and angiographic outcomes. 22:135-143. 1993
- Outcome of patients with diabetes-mellitus and acute myocardial-infarction treated with thrombolytic agents. 21:920-925. 1993
- Thrombolytic therapy for women with myocardial-infarction - is there a gender-gap. 22:1780-1787. 1993
- Thrombosis of a flexible coil coronary stent - frequency, predictors and clinical outcome. 21:622-627. 1993
- Toward the quiescent coronary plaque. 22:1228-1241. 1993
- Abrupt vessel closure after directional coronary atherectomy. 19:1372-1379. 1992
- Abrupt vessel closure complicating coronary angioplasty - clinical, angiographic and therapeutic profile. 19:926-935. 1992
- Accelerated plasminogen-activator dose regimens for coronary thrombolysis. 19:482-489. 1992
- Cardiogenic-shock complicating acute myocardial-infarction - the use of coronary angioplasty and the integration of the new support devices into patient-management. 19:647-653. 1992
- Confronting the issues of patient safety and investigator conflict-of-interest in an international clinical-trial of myocardial reperfusion. 19:1123-1128. 1992
- Experimental-models of coronary-artery restenosis. 19:418-432. 1992
- Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. 20:460-466. 1992
- Mechanism of benefit of combination thrombolytic therapy for acute myocardial-infarction - a quantitative angiographic and hematologic study. 20:1305-1312. 1992
- The restenosis paradigm revisited - an alternative proposal for cellular mechanisms. 20:1284-1293. 1992
- A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen-activator therapy in acute myocardial-infarction. 17:467-473. 1991
- Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomy. 18:1183-1189. 1991
- Clinical-experience with the palmaz-schatz coronary stent. 17:B155-B159. 1991
- Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions. 17:B126-B131. 1991
- Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial-infarction. 18:1594-1601. 1991
- Limitations of thrombolytic therapy for acute myocardial-infarction complicated by congestive-heart-failure and cardiogenic-shock. 18:1077-1084. 1991
- Myocardial-infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. 17:304-312. 1991
- Percutaneous support devices for high-risk or complicated coronary angioplasty. 17:770-780. 1991
- Prospects for the use of antagonists to the platelet glycoprotein-IIb glycoprotein-IIIa receptor to prevent postangioplasty restenosis and thrombosis. 17:B89-B95. 1991
- Treatment of recurrent ischemia after thrombolysis and successful reperfusion for acute myocardial-infarction - effect on in-hospital mortality and left-ventricular function. 17:752-757. 1991
- Fate of patients with acute myocardial-infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. 16:770-778. 1990
- Initial report of the national-registry-of-elective-cardiopulmonary bypass supported coronary angioplasty. 15:23-29. 1990
- Precordial st segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. 16:1538-1544. 1990
- Stroke and acute myocardial-infarction in the thrombolytic era - clinical correlates and long-term prognosis. 16:533-540. 1990
- Combined tissue-type plasminogen-activator and prostacyclin therapy for acute myocardial-infarction. 14:877-884. 1989
- Coronary angioplasty as primary therapy for acute myocardial-infarction 6 to 48 hours after symptom onset - report of an initial experience. 13:1122-1126. 1989
- From myocardial salvage to patient salvage in acute myocardial-infarction - the role of reperfusion therapy. 14:1382-1388. 1989
- Implications for patient triage from survival and left-ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial-infarction. 13:1251-1259. 1989
- Intracoronary stents - will they fulfill their promise as an adjunct to angioplasty. 13:1425-1430. 1989
- Randomized, double-blind, placebo-controlled trial of tissue plasminogen-activator in unstable angina. 13:434-441. 1989
- Reperfusion momentum - lessons from the randomized trials of immediate coronary angioplasty for myocardial-infarction. 14:1572-1578. 1989
- Sudden paradoxic clinical deterioration during angioplasty of the occluded right coronary-artery in acute myocardial-infarction. 14:1202-1209. 1989
- Thrombolysis and angioplasty in myocardial-infarction (tami-1) trial - influence of infarct location on arterial patency, left-ventricular function and mortality. 13:12-18. 1989
- Cost and procedure implications of thrombolytic therapy for acute myocardial-infarction. 12:A58-A68. 1988
- Emergency coronary-artery bypass-surgery preserves global and regional left-ventricular function after intravenous tissue plasminogen-activator therapy for acute myocardial-infarction. 11:899-907. 1988
- Insights derived from the thrombolysis and angioplasty in myocardial-infarction (tami) trials. 12:A24-A31. 1988
- Predictors of success for coronary angioplasty performed for acute myocardial-infarction. 12:1407-1415. 1988
- A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen-activator (activase) in acute myocardial-infarction. 9:1205-1213. 1987
- Community-hospital administration of intravenous tissue plasminogen-activator in acute myocardial-infarction - improved timing, thrombolytic efficacy and ventricular-function. 10:1173-1177. 1987
- Multicenter study of percutaneous trans-luminal angioplasty for right coronary-artery ostial stenosis. 9:1214-1218. 1987
- Thrombolysis and angioplasty in myocardial-infarction (tami) trial. 10:B65-B74. 1987
- Doppler echocardiographic measurement of aortic-valve area in aortic-stenosis - a noninvasive application of the gorlin formula. 8:1059-1065. 1986
- Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen-activator - importance of coronary angioplasty. 6:426-433. 1985
- Thrombolysis with recombinant tissue plasminogen-activator in atherosclerotic thrombotic occlusion. 5:85-91. 1985
- Immediate improvement of dysfunctional myocardial segments after coronary revascularization - detection by intraoperative trans-esophageal echocardiography. 4:1123-1134. 1984